PARP inhibitors in breast cancer: BRCA and beyond

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• DNA repair mechanisms are vital for cellular survival, distinguishing between repairable damage and apoptosis.
• Poly(adenosine diphosphate [ADP]-ribose) polymerases (PARPs) are key enzymes in base excision repair pathways.
• PARP inhibition triggers cell death in cancers with specific DNA repair defects, like BRCA mutations.

Purpose of the Study:

• To review preclinical data and rationale for PARP inhibitor use in cancer treatment.
• To discuss the clinical development status of PARP inhibitors for breast cancer.
• To explore future research directions for PARP inhibitors in oncology.

Main Methods:

• Literature review of preclinical data and clinical trial information.
• Searches conducted in PubMed, clinicaltrials.gov, and major oncology conference proceedings.
• Focus on PARP inhibitors' role in BRCA-mutated cancers, triple-negative breast cancer, and combination therapies.

Main Results:

• PARP inhibitors induce synthetic lethality in tumors with deficient homologous recombination repair (e.g., BRCA mutations).
• Combination therapy with DNA-damaging agents potentiates the anti-cancer effects of PARP inhibitors.
• PARP inhibitors are under investigation as monotherapy and in combination for various breast cancer subtypes.

Conclusions:

• PARP inhibitors represent a significant therapeutic strategy for specific cancer types, particularly those with DNA repair deficiencies.
• Clinical development is advancing, with ongoing trials evaluating efficacy and safety in breast cancer.
• Further research is warranted to optimize PARP inhibitor use and expand their application in cancer treatment.